IL6 is a pleiotropic cytokine which has been implicated in ligand-independent activation of androgen receptor in prostate cancer cells. Here, we present the evidence that two cytoplasmic kinases Pim1 and Etk are involved in this process. We showed that Pim1 is expressed in all prostate cancer cell lines examined. Both the expression level and the kinase activity of Pim1 are regulated by IL6 in these cells. Furthermore, we showed that IL6 downstream tyrosine kinase Etk can induce tyrosine phosphorylation of Pim1 which is correlated with its kinase activity. Mutation of the conserved Tyrosine 218 in the activation loop results in reduced kinase activity of Pim1. Interestingly, Etk can also be activated by Pim1 when they are coexpressed in prostate cancer cells, suggesting a possible positive feedback loop between Etk and Pim1. It appears that both Pim1 and Etk are required for IL6-induced activation of androgen receptor-mediated transcription in prostate cancer cells because overexpression of the kinasedeficient form of either Pim1 or Etk dramatically blocks the IL6 effect. Coexpression of the two kinases together but neither one alone is sufficient to activate AREcontaining promoter. Taken together, our data suggest a synergism of Ser/Thr kinase Pim1 and tyrosine kinase Etk in IL6 signaling and provide new insights into ligandindependent activation of androgen receptor in prostate cancer cells.
Introduction
IL6 is a pleiotropic cytokine originally identified as a regulator of immune and inflammatory responses (Hirano, 1992) . IL6 induces cellular differentiation and exerts growth inhibition, growth stimulation, and antiapoptosis in different cellular contexts. Deregulation of IL6 has been reported in several human carcinomas including myeloma, ovarian cancer and breast cancer (Abe et al., 1991; Plante et al., 1994; Ueda et al., 1994) . Mounting evidence suggests that IL6 may also play a role in regulation of prostate cancer (PCA) cell growth and metastasis. Prostatic tumor characteristically metastasizes to bone, lymph node and liver, where IL6 is present (Siegall et al., 1990; Siegsmund et al., 1994) . Patients with advanced PCA have elevated systemic serum IL6, which is correlated with the tumor burden (Akimoto et al., 1998; Adler et al., 1999) . Interestingly, the expression of IL6 is regulated by androgen. With aging, serum androgen levels decline while serum IL6 levels increase (Daynes et al., 1993) . The orchiectomy in a murine model results in the elevated serum IL6, which is reversible by testosterone administration (Bellido et al., 1995) . A recent study showed that androgen suppresses the expression of IL6 through androgen receptor and IkB in a PCA cell line LNCaP (Keller et al., 1996) . A report from Pastan's lab showed that IL6 receptors are expressed at significant level in 100% of PCA samples and cell lines surveyed (Siegall et al., 1990; Siegsmund et al., 1994) . The IL6 autocrine loop is present in all androgen-independent PCA cells tested so far, suggesting an intimate link between IL6 autocrine loop and androgen-independent phenotype (Okamoto et al., 1998) . This is further supported by a recent report that a neutralizing antibody against IL6 inhibits the growth of PC3 cells in nude mice ). IL6 has also been shown to increase nuclear androgen receptor (AR) level in PCA cells and activate AR-mediated transcription activity in LNCaP cells in the absence of androgen (Chen et al., 2000; Lin et al., 2001; Ueda et al., 2002) . However, the detailed mechanisms by which IL6 activates ligand-independent activation of AR remain elusive although p300 has been shown required for this process (Debes et al., 2002) . Several major signaling pathways are activated by IL6 in PCA cells, including PI3-kinase, JAK-Stats and Ras-MAPK pathways . In our previous studies, we showed that IL6 induces the activation of tyrosine kinase Etk through the PI3-kinase, and Etk is required for IL6-induced neuroendocrine differentiation. Etk has also been implicated in regulation of cell migration, cytoskeletal reorganization and vesicle trafficking (Chen et al., 2001; Kim et al., 2002; Yang et al., 2002) . A recent report also suggested a role of Etk in androgen-independent growth of PCA cells induced by neuropeptides (Lee et al., 2001) .
The serine/threonine kinase Pim1 was originally identified as a frequently activated cellular gene by retrovirus insertion (Cuypers et al., 1984) . Our current knowledge on Pim1 kinase is largely derived from studies in immune systems. The transgenic mice overexpressing Pim1 under the control of the immunoglobin enhancer Eu are highly susceptible to developing T lymphoma after MuLV infection and chemical carcinogen exposure (Breuer et al., 1989) . Under physiological conditions, the expression of Pim1 is rapidly induced by various cytokines, including IL2, IL3 and IL6. The proliferative response to these cytokines is impaired in cells from Pim1-deficient mice (Lilly et al., 1992; . Pim1 has been shown to play a critical role in IL6-initiated cell cycle progression and antiapoptosis in B cells (Shirogane et al., 1999) . Recently, Pim1 has emerged as a potential important kinase in prostate cancer. In a recent gene and tissue array study of 738 prostate tumor specimens, Pim1 was found upregulated in more than 50% of the samples examined (Dhanasekaran et al., 2001) , strongly suggesting a potential role of Pim1 in prostate cancer progression. However, very little is known about the functions of Pim1 in prostate cancer. Here, we present the evidence that Pim1 kinase is regulated by IL6 in prostate cancer cells and involved in IL6-induced ligand-independent activation of androgen receptor-mediated transcriptional activity.
Materials and methods

Cell culture and transfection
All cell lines used in this study were purchased from ATCC. COS-1 cells were maintained in DMEM supplemented with 10% fetal bovine serum. LNCaP and PC3 cells were maintained in RPMI1640 supplemented with 10% fetal bovine serum. 22Rv1 cells were maintained in RPMI1640 supplemented with 10% heat-inactivated fetal bovine serum. Transfections were performed by using Fugene 6 (Roche) according to the manufacturer's instruction.
DNA constructs and antibodies
T7-tagged Etk and its mutants were cloned in pcDNA3 vector as described previously (Qiu et al., 1998) . Flag-tagged Pim1 and Pim1KM constructs were kindly provided by Dr Hirano (Shirogane et al., 1999) . Site mutagenesis was carried out by using PCR-based QuickChange kit (Stratagene). Mutations were verified by sequencing. Anti-T7 antibody was purchased from Novagen. Anti-Flag antibody was from Sigma. AntiPim1 and HRP conjugated anti-phosphotyrosine antibody were from Santa Cruz. Polyclonal Etk antibody was developed as described previously (Qiu et al., 1998) . The Probasin luciferase reporter construct ARR2-Luc was generated by insertion of the minimal probasin promoter ARR2, kindly provided by Dr R Matusik (Zhang et al., 2000) into the polyclonal linker region of pGL2. A promoter-less RL (Promega) was used as the internal control.
Immunoprecipitation and Western blot
The transfected cells were lysed in the buffer (20 mM Tris/HCl pH 7.4,. 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 1 mM Na 3 VO 4 , 1 mg/ml aprotinin, 1 mg/ml leupterin and 1mM PMSF). Insoluble material was removed by centrifugation, and antibodies were added to lysates for 1 h at 41C. Antibodies were collected with protein A or protein Gsepharose beads, and protein complexes were washed three times at 41C with the lysis buffer. Immunoblotting was performed as previously described . Briefly, blots were incubated with primary antibodies, 1 : 5000 dilution of anti-T7 tag, 1 : 2000 dilution of anti-phosphotyrosine, 1 : 1000 dilution of anti-Flag tag, 1 : 100 dilution of anti-Pim1 at room temperature for 1 h, and followed by detection with horseradish peroxidase-conjugated secondary antibody.
In vitro kinase (IVK) assay
Pim1 IVK assays were performed as reported previously (Zhu et al., 2002) . Briefly, anti-Flag immunoprecipitates were washed twice with Pim1 kinase buffer (25 mM HEPES, 10 mM MgCl 2 , 1 mM DTT). The immune complex was then incubated at room temperature for 15 min in 30 ml of the kinase buffer with 0.1 mg/ml histone1 and 10 mCi of [g-32 P]ATP. The reaction was separated by 10% SDS-polyacrylamide gel electrophoresis. After the gels were dried, the phosphorylation of histone1 was visualized by autoradiography. Etk IVK assays were carried out as described previously (Qiu et al., 1998) .
Luciferase assay
LNCaP cells grown in a 24-well plate coated with polylysine were transfected with ARR2-Luc and the internal control (a promoter-less RL) in the medium containing 10% charcoalstripped FBS (Hyclone). The conventional interanal control TK-RL was replaced by a promoter-less RL because of the strong response of TK promoter to IL6. 24 h post-transfection, the cells were incubated with fresh phenol-red free serum-free medium with or without IL-6 (10 ng/ml) for 12 h. Luciferase activities were measured by using dual luciferase assay system according to the manufacturer's instruction (Promega). The results are presented as the fold induction that is the relative luciferase activity of the treated cells divided by that of the control. Lucifease assays were carried out in triplicates.
Cell proliferation assay 22Rv1 cells were transfected with vector, T7-EtkKQ and FLAG-Pim1KM, respectively. After 24 h, the transfected cells were seeded on 96-well plates and incubated in RPMI1640 supplemented with 10% fetal bovine serum for 24 h in order to allow the cells to attach. The cells were then cultured in serumfree medium with or without 25 ng/ml IL6 for another 24 h. The proliferation rate was measured using WST-1 reagent (Roche Molecular Biochemicals). An aliquot of cells were lysed and followed by Western blotting with anti-T7 or antiFlag to monitor the transfection efficiency.
Results
It has been reported that Pim1 is upregulated in 50% of prostate tumor samples by using high-density tissue microarrays (Dhanasekaran et al., 2001) . Therefore, we examined the expression of Piml in several wellestablished prostate cancer cell lines including LNCaP, Role of Pim1 and Etk in IL6-induced AR activation O Kim et al 22Rv1 and PC3 cells by Western blot using a monoclonal antibody specific for Pim1. Consistent with previous studies (Amson et al., 1989; Saris et al., 1991) , Pim1 is detected as doublets around 33 kDa in these human prostate cancer cell lines. There is very minimal expression of Pim1 in LNCaP while much higher in 22Rv1 and PC3 (Figure 1a) . Based on previous studies in immune systems, Pim1 is rapidly induced by various cytokines (Lilly et al., 1992; Sato et al., 1993; Jaster et al., 1999; Matikainen et al., 1999) . Therefore, we examined the effect of IL6 on Pim1 expression in PCA cells. As shown in Figure 1b , Pim1 protein level is dramatically increased in LNCaP cells after 12 h treatment with 10 ng/ml of IL6. Similar induction of Pim1 was also observed in PC3 cells when they were treated with 50 ng/ml IL6, although the basal level of Pim1 is significantly higher in these cells. We further performed semiquantitative RT-PCR analysis to confirm that the increase of Pim1 expression is resulted from IL6-induced transcription of Pim1 mRNA (Figure 1c ). To test whether the higher basal level of Pim1 expression is resulted from the IL6 autocrine loop present in PC3 (Okamoto et al., 1998) , the cells were treated with IL6 neutralizing antibody for 24 h. Our results show that IL6 neutralizing antibody significantly suppressed the Pim1 expression in PC3 (Figure 1d ). Taken together, these data suggest that IL6 can induce Pim1 expression in prostate cancer cells.
To test whether Pim1 kinase activity can also be promoted by IL6 treatment, the flag-tagged wild-type Pim1 and kinase-inactive Pim1KM were transfected into LNCaP cells, respectively. The cells were then serumstarved overnight at 24 h post-transfection and treated with IL6 (200 ng/ml) for 15 min. Pim1 kinase was immunoprecipitated by anti-Flag and IVK kinase assays were performed using Histone1 as a substrate. As shown in Figure 2a , Pim1 kinase activity was dramatically increased by IL6 treatment while the kinase-inactive Pim1KM showed virtually no activity. To investigate what signaling molecules may be involved in Pim1 activation induced by IL6, we examined the effects of tyrosine kinase Etk on Pim1 activation because Etk is known to be activated by IL6 in prostate cancer cells. Pim1 and Etk were cotransfected into LNCaP cells. Figure 2b showed that cotransfection of Etk with Pim1 dramatically increased the kinase activity of Pim1. Interestingly, tyrosine phosphorylation of Pim1 is also significantly increased in the presence of Etk (Figure 2c) . However, the kinase-inactive Etk (EtkKQ) or another tyrosine kinase FAK has little effect on tyrosine phosphorylation of Pim1, suggesting that Etk may be responsible to induce tyrosine phosphorylation of Pim1 which is correlated with activation of Pim1 kinase activity. To confirm that tyrosine phosphorylation of Pim1 also occurs under physiological conditions, we examined whether IL6 induces the phosphorylation of Pim1 in 22Rv1 and PC3 cells. As shown in Figure 2d , tyrosine phosphorylation of the endogenous Pim1 was detected at 15 min after IL6 treatment in both types of cells. The phosphorylation seemed to be transient because the phosphorylation disappeared at 30 min after the treatment. To investigate whether tyrosine phosphorylation of Pim1 plays a role in the activation of its kinase activity, we mutated the tyrosine residue Y218 that is located in the activation loop of the kinase domain and conserved among PIM family kinases (Figure 3a) . Figure 3b showed that the substitution of Y218 to phenylalanine dramatically reduced both tyrosine phosphorylation and kinase activity of Pim1 induced by Etk. These data suggest that tyrosine phosphorylation of Y218 by Etk may be important for the activation of Pim1 kinase activity.
We also examined the effects of Pim1 on Etk by contransfecting Etk and Pim1 into LNCaP cells. As shown in Figure 4 , tyrosine phosphorylation of Etk is dramatically increased by Pim1 but not the kinase- Figure 5a shows that coexpression of the kinase inactive EtkKQ significantly inhibited IL6-induced activation of Pim1 kinase activity. On the other hand, the kinase-inactive Pim1KM also blocked IL6-induced activation of Etk in these cells (Figure 5b ). These data suggest that Etk activity for Pim1 activation and the same is true vice versa.
It has been shown that IL6 can induce ligandindependent activation of androgen receptor-mediated transcriptional activity (Hobisch et al., 1998) . We like to know whether Pim1 and Etk are involved in IL6-induced AR activation. Kinase-inactive Etk (EtkKQ) or . At 24 h post-transfection, the cells were serum starved for 6 h and treated with IL6 (200 ng/ ml) for 15 min. The cell lysates were subjected to immunoprecipitation with anti-Flag, followed by IVK using H1 as a substrate. The amount of Pim1 in each sample was determined by immunoblotting with antiFlag (bottom). (b) The effects of Etk on Pim1 kinase activity. Flagtagged Pim1 was cotransfected with vector, T7-Etk or kinase-inactive T7-EtkKQ into LNCaP cells. At 24 h post-transfection, the cells were serum starved for another 24 h before they were lysed. Pim1 IVK was performed as above. The level of Pim1 and Etk in the cells were monitored by immunoblotting with anti-Flag and anti-Etk, respectively. (c) Etk induces tyrosine phosphorylation of Pim1. Flag-tagged Pim1 was cotransfected with vector control, T7-Etkwt, kinase-inactive T7-EtkKQ, HA-FAK and kinase-inactive HA-FAK-KD into LNCaP cells, respectively. At 24 h post-transfection, the cells were serum starved for 24 h. The cell lysates were subjected to immunoprecipitation with anti-Flag, followed by immunoblotting with antiphosphotyrosine (pY). The protein levels of Pim1, Etk and FAK in the cells were determined by immunoblotting of total cell lysates with antiFlag, anti-T7 or anti-HA antibodies. (d) IL6 induces tyrosine phosphorylation of endogenous Pim1 in PCA cells. Subconfluent PC3 and 22Rv1 cells were serum starved for 6 h, followed by treatment with IL6 (100 ng/ml) for the times indicated. The cell lysates were subjected to immunoprecipitation with anti-Pim1, followed by immunoblotting with antiphosphotyrosine antibody. The amount of Pim1 in each sample was monitored by immunoblotting with anti-Pim1 Figure 6a shows that, in vector-transfected control cells, IL6 induced about 20-fold increase of transcription activity of the androgen receptor-dependent activity. However, in the presence of kinase-inactive Pim1 or Etk, the IL6 effects were dramatically blocked, suggesting that kinase activities of both Pim1 and Etk seem to be required for IL6-induced AR activation. In the meantime, overexpressing Pim1 or Etk alone had very minimal effect on ARmediated transcription (Figure 6b ). However, coexpression of Pim1 and Etk resulted in significant increase of the transcription activity. These data suggest the synergistic effects of Etk and Pim1 on activation of ARE-containing promoter. Furthermore, we examined the expression level of PSA in EtkDN cells, which is a LNCaP derivative stably expressing a dominant-negative Etk mutant (Xue et al., 1999) , in response to IL6. Figure 4 Effects of Piml on Etk kinase activity. T7-Etk was cotransfected with vector control, Pim1 or kinase inactive Pim1KM into 22Rv1 cells. At 24 h post-transfection, the cells were serum starved for 24 h. The cell lysates were immunoprecipitated with anti-Etk antibody, followed by immunoblotting with anti-pY antibody (top). The autophosphorylation activity of Etk was determined by IVK (middle). The protein level of Etk was monitored by immunoblotting with anti-Etk (bottom) Figure 5 Requirement of both Etk and Pim1 for IL6 signaling in PCA cells. (a) Etk kinase activity is required for IL6-induced Pim1 activation. FLAG-Pim1 was cotransfected with EtkKQ ( þ ) or vector (À) into LNCaP cells. At 24 h post-transfection, the cells were serum starved for 6 h and followed by treatment with IL6 for 15 min. Pim1 kinase activity was determined by IVK assay as described in Figure 2. (b) Pim1 kinase activity is required for IL6-induced Etk activation. T7-Etk was cotransfected with Pim1KM ( þ ) or vector (À) into LNCaP cells. The cells were then treated as above. Etk kinase activity was determined as described in Figure 4 Figure 6 Effects of Piml and Etk on androgen receptor-mediated transcriptional activity. (a) Kinase activity of Pim1 and Etk are required for IL-6-induced ARE activity. ARR2-Luc and promoterless-RL were transfected with the vector control, kinase inactive Pim1KM or Etk KQ into LNCaP cells grown in the complete medium containing 10% of charcoal-stripped FBS. At 24 h posttransfection, cells were subjected to incubation with fresh phenolred free serum-free medium with or without IL6 (10 ng/ml) for 12 h. Luciferase assays were performed according to the manufacturer's instruction (Promega). The data were expressed as the relative luciferase activity. The error bars represent the mean7s.d. of three independent experiments. (b) Synergistic effects of Piml and Etk on ARE-containing promoter activity. ARR2-Luc and promoter-less-RL were transfected with the indicated plasmids into LNCaP cells as above. At 24 h post-transfection, the cells were subjected to serum starvation for 12 h. Luciferase assays were performed as above. (c) Requirement of Etk kinase activity in IL6-induced PSA expression. LNCaP(LN) and its derivative EtkDN were cultured in the phenol red-free medium containing 10% charcoal-stripped FBS for 3 days. The cells were then treated with or without 50 ng/ml of IL6 in serum-free medium for 24 h. The levels of PSA in these cells were determined by immunoblotting with anti-PSA. The same blot was also probed with anti-actin or anti-T7 antibodies to monitor the sample loading (anti-actin) or the expression of the dominantnegative Etk (anti-T7)
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Consistent with previous report, IL6 induces PSA expression in LNCaP cells. However, no elevation of PSA expression in IL6-treated EtkDN cells was detected (Figure 6c ). These data suggest that Etk kinase activity is required for IL6-induced PSA expression. To test whether Etk and Pim1 are required for IL6-induced proliferation of PCA cells. The vector control, Pim1KM or EtkKQ was transfected into 22Rv1 cells. The effects of IL6 on the proliferation of these cells were determined by the WST assay. As shown in Figure 7 , IL6 treatment resulted in increased cell proliferation of vector-transfected cells by about 45%. This effect was diminished in the cells transfected with either EtkKQ or PimKM. Cotransfection of two kinase-dead mutants together further inhibited the cell proliferation. These results suggest that both Etk and Pim1 are required for IL6 promoted proliferation of 22Rv1 cells.
Discussion
Prostate cancer is the most commonly diagnosed cancer among men. Understanding the biological mechanisms involved in androgen-independent growth, tumor progression and metastasis has emerged as a fundamental and urgent issue in prostate cancer research. Mounting evidence suggests that IL6 may play an important role in ligand-independent activation of androgen receptor in prostate cancer cells. In this report, we presented the evidence of the synergistic effect of cytoplasmic kinases Pim1 and Etk on ligand-independent activation of androgen receptor induced by IL6. We showed that Pim1 is expressed in all PCA cell lines tested. The expression level of Pim1 in LNCaP cells is relatively lower than that in 22Rv1 and PC3. It is noteworthy that 22Rv1 and PC3 can usually form tumors when they are subcutaneously injected into male nude mice while LNCaP can hardly form any detectable tumors. These data suggest a possible correlation between the expression level of Pim1 and the tumorigenicity of these prostate cancer cells. Furthermore, the expression of Pim1 in PC3 cells appears to be regulated by IL6 autocrine loop because the neutralizing antibody against IL6 significantly diminished Pim1 expression in PC3 cells. IL6 not only regulates Pim1 expression at the transcriptional level, but also modulates the Pim1 kinase activity through its downstream tyrosine kinase Etk. We showed that Etk can induce tyrosine phosphorylation of Pim1 on Y218 in its activation loop, which is required for the activation of Pim1 kinase activity. Interestingly, Pim1 can also in turn enhance Etk kinase activity. Our preliminary data showed that Pim1 and Etk can form a complex which is detectable in a coimmunoprecipitation experiment. However, we were unable to detect the direct interaction of these two kinases in the In vitro GST-pulldown assay, implying that Pim1 might be associated with Etk through other protein(s). Identification of the intermediate protein(s) would help us to understand how these kinases activate each other. We also showed that the kinase activity of both Etk and Pim1 seem to be required for IL6-induced ligandindependent activation of AR transcriptional activity. However, overexpression of Etk or Pim1 alone is not sufficient for AR activation, suggesting a synergism between these two kinases is essential for AR activation. We were unable to detect phosphorylation of AR in neither Etk nor Pim1 IVK assay, implying that other protein(s) regulated by these kinases are responsible for the direct activation of AR. Further investigation on the downstream effectors of Etk and Pim1 will be required to reveal how Etk and Pim1 exert their influence on AR. Our work suggests that androgen-independent activation of AR in PCA cells is a complicated process which requires the involvement of multiple factors. Understanding the mechanisms by which the key factors regulate the downstream events leading to activation of AR will be essential for developing more effective intervention against hormone refractory prostate cancer. Role of Pim1 and Etk in IL6-induced AR activation O Kim et al
